Gavisus Suspension: Each 10 ml suspension contains Sodium Alginate BP 500 mg, Sodium Bicarbonate BP 267 mg & Calcium Carbonate BP 160 mg.
Gavisus DX Suspension: Each 10 ml suspension contains Sodium Alginate BP 500 mg, Sodium Bicarbonate BP 213 mg & Calcium Carbonate BP 325 mg.
Gavisus Chewable Tablet: Each chewable tablet contains Sodium Alginate BP 250 mg, Sodium Bicarbonate BP 133.50 mg & Calcium Carbonate BP 80 mg.
The mode of action of the product is physical and does not depend on absorption into the systemic circulation. On ingestion, the product reacts rapidly with gastric acid to form a raft of Alginic acid gel having a near neutral pH and which floats on the stomach contents quickly and effectively impeding gastro-esophageal reflux, for up to 4 hours. In severe cases, the raft itself may be refluxed into the esophagus in preference to the stomach contents and exert a demulcent effects.
Gastric reflux, heartburn, flatulence associated with gastric reflux, heartburn of pregnancy, all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.
Route of administration: Oral.
Gavisus Suspension: Adult and children over 12 years: 10-20 ml after meals and at bedtime, up to four times a day.
Children 6 to 12 years: 5-10 ml after meals and at bedtime, up to four times a day.
Children under 6 years: Not recommended.
Elderly: No dosage modification is required for this age group.
Gavisus DX Suspension: Adults and children 12 years and over: 10-20 ml after meals and at bedtime, up to four times per day.
Children under 12 years: Should be given only on medical advice.
Elderly: No dose modifications necessary for this age group.
Hepatic Impairment: No dose modification necessary.
Renal Insufficiency: Caution if highly restricted salt diet is necessary.
Gavisus Tablet: Adult and children 12 years and over: 2-4 tablets after meals and at bedtime, up to four times per day.
Children under 12 years: Should be given only on medical advice.
Elderly: No dosage modification is required for this age group.
Hepatic Impairment: No dosage modification necessary.
Renal Insufficiency: Caution if highly restricted salt diet is necessary.
With medicine: A time-interval of 2 hours should be considered between this drug intake and the administration of other medicinal products especially Tetracyclines, Digoxine, Fluoroquinolone, Iron-salt, Ketoconazole, Neuroleptics, Thyroid Hormones, Penicillamine, beta-blockers (Atenolol, Metoprolol, Propranolol), Glucocorticoid, Chloroquine and Biphosphonates (diphosphonates) and Estramustine.
With food & others: Milk and dairy products may interact with this medicine.
Overdose:
In the event of over dosage symptomatic treatment should be given. The patient may notice abdominal distension.
Pregnancy: Clinical studies in more than 500 pregnant women as well as a large amount of data from post marketing experience indicate no malformative nor feto/neonatal toxicity of the active ingredients. This drug can be used during pregnancy, if clinically needed.
Lactation: No effects of the active substances have been shown in breastfed newborns/ infants of treated mothers. This drug can be used during breast-feeding.
Gavisus Suspension is not recommended to use under 6 years of age. In case of Gavisus DX Suspension & tablet, administration in children under 12 should be only on medical advice.
If symptoms do not improve after 7 days, the clinical situation should be reviewed. These medications are high in Sodium. This should be taken into account when highly restricted salt diet is recommended. e.g. in some cases of congestive cardiac failure and renal impairment. Besides, these medications contain Calcium Carbonate. Care needs to be taken in treating patients with hypercalcemia, nephrocalcinosis and recurrent calcium containing renal calculi.
Store below 30°C temperature & dry place, protected from light. Keep all medicines out of reach of the children.